Seagen/Genmab’s confirmatory cervical cancer trial is toplined positive, putting up a fresh roadblock for Iovance’s accelerated filing plans.

Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.

Novartis looks set to hand nisevokitug rights back to Xoma, though plenty of work on TGF-β continues.

However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.

Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.

Curiously, however, higher dosing does not seem to be the answer to the company’s relapse problem.